clinical trial · NCT07374549
SYS6002 vs PADCEV in Patients With Advanced Urothelial Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.·phase2·not yet recruiting·n = 100
Advanced Urothelial CarcinomaSYS6002enfortumab vedotin
brief summary
This study is a randomized, open-label, controlled, multicenter phase II clinical trial, which aims to evaluate the safety and efficacy of SYS6002 versus enfortumab vedotin in the treatment of participants with advanced urothelial carcinoma. This study has not yet been submitted for ethical review. The current registration is a pre-registration. Recruitment will be initiated only after formal approval is obtained from the relevant Ethics Committee or Institutional Review Board.
started
Jun 20, 2026
primary completion
Jun 1, 2028
completion
Dec 1, 2028
last updated
Jan 29, 2026
official title
A Randomized, Open-Label, Controlled, Multicenter Phase 2 Trial of SYS6002 Versus PADCEV in Patients With Advanced Urothelial Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol